Eintrag weiter verarbeiten
A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmaconutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients w...
Gespeichert in:
| Zeitschriftentitel: | Cancer Epidemiology, Biomarkers & Prevention |
|---|---|
| Personen und Körperschaften: | , , , , , , , , |
| In: | Cancer Epidemiology, Biomarkers & Prevention, 15, 2006, 5, S. 1030-1034 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Mantovani, Giovanni Macciò, Antonio Madeddu, Clelia Gramignano, Giulia Lusso, Maria Rita Serpe, Roberto Massa, Elena Astara, Giorgio Deiana, Laura Mantovani, Giovanni Macciò, Antonio Madeddu, Clelia Gramignano, Giulia Lusso, Maria Rita Serpe, Roberto Massa, Elena Astara, Giorgio Deiana, Laura |
|---|---|
| author |
Mantovani, Giovanni Macciò, Antonio Madeddu, Clelia Gramignano, Giulia Lusso, Maria Rita Serpe, Roberto Massa, Elena Astara, Giorgio Deiana, Laura |
| spellingShingle |
Mantovani, Giovanni Macciò, Antonio Madeddu, Clelia Gramignano, Giulia Lusso, Maria Rita Serpe, Roberto Massa, Elena Astara, Giorgio Deiana, Laura Cancer Epidemiology, Biomarkers & Prevention A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmaconutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress Oncology Epidemiology |
| author_sort |
mantovani, giovanni |
| spelling |
Mantovani, Giovanni Macciò, Antonio Madeddu, Clelia Gramignano, Giulia Lusso, Maria Rita Serpe, Roberto Massa, Elena Astara, Giorgio Deiana, Laura 1055-9965 1538-7755 American Association for Cancer Research (AACR) Oncology Epidemiology http://dx.doi.org/10.1158/1055-9965.epi-05-0538 <jats:title>Abstract</jats:title> <jats:p>Purpose: To test the efficacy and safety of an integrated treatment based on a pharmaconutritional support, antioxidants, and drugs, all given orally, in a population of advanced cancer patients with cancer-related anorexia/cachexia and oxidative stress.</jats:p> <jats:p>Patients and Methods: An open early-phase II study was designed according to the Simon two-stage design. The integrated treatment consisted of diet with high polyphenols content (400 mg), antioxidant treatment (300 mg/d α-lipoic acid + 2.7 g/d carbocysteine lysine salt + 400 mg/d vitamin E + 30,000 IU/d vitamin A + 500 mg/d vitamin C), and pharmaconutritional support enriched with 2 cans per day (n-3)-PUFA (eicosapentaenoic acid and docosahexaenoic acid), 500 mg/d medroxyprogesterone acetate, and 200 mg/d selective cyclooxygenase-2 inhibitor celecoxib. The treatment duration was 4 months. The following variables were evaluated: (a) clinical (Eastern Cooperative Oncology Group performance status); (b) nutritional [lean body mass (LBM), appetite, and resting energy expenditure]; (c) laboratory [proinflammatory cytokines and leptin, reactive oxygen species (ROS) and antioxidant enzymes]; (d) quality of life (European Organization for Research and Treatment of Cancer QLQ-C30, Euro QL-5D, and MFSI-SF).</jats:p> <jats:p>Results: From July 2002 to January 2005, 44 patients were enrolled. Of these, 39 completed the treatment and were assessable. Body weight increased significantly from baseline as did LBM and appetite. There was an important decrease of proinflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-α, and a negative relationship worthy of note was only found between LBM and IL-6 changes. As for quality of life evaluation, there was a marked improvement in the European Organization for Research and Treatment of Cancer QLQ-C30, Euro QL-5DVAS, and multidimensional fatigue symptom inventory-short form scores. At the end of the study, 22 of the 39 patients were “responders” or “high responders.” The minimum required was 21; therefore, the treatment was effective and more importantly was shown to be safe.</jats:p> <jats:p>Conclusion: The efficacy and safety of the treatment have been shown by the study; therefore, a randomized phase III study is warranted. (Cancer Epidemiol Biomarkers Prev 2006;15(5):1030–4)</jats:p> A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmaconutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress Cancer Epidemiology, Biomarkers & Prevention |
| doi_str_mv |
10.1158/1055-9965.epi-05-0538 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDU1LTk5NjUuZXBpLTA1LTA1Mzg |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDU1LTk5NjUuZXBpLTA1LTA1Mzg |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Association for Cancer Research (AACR), 2006 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2006 |
| issn |
1055-9965 1538-7755 |
| issn_str_mv |
1055-9965 1538-7755 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
mantovani2006aphaseiistudywithantioxidantsbothinthedietandsupplementedpharmaconutritionalsupportprogestagenandanticyclooxygenase2showingefficacyandsafetyinpatientswithcancerrelatedanorexiacachexiaandoxidativestress |
| publishDateSort |
2006 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Cancer Epidemiology, Biomarkers & Prevention |
| source_id |
49 |
| title |
A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmaconutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress |
| title_unstemmed |
A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmaconutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress |
| title_full |
A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmaconutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress |
| title_fullStr |
A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmaconutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress |
| title_full_unstemmed |
A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmaconutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress |
| title_short |
A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmaconutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress |
| title_sort |
a phase ii study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress |
| topic |
Oncology Epidemiology |
| url |
http://dx.doi.org/10.1158/1055-9965.epi-05-0538 |
| publishDate |
2006 |
| physical |
1030-1034 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>Purpose: To test the efficacy and safety of an integrated treatment based on a pharmaconutritional support, antioxidants, and drugs, all given orally, in a population of advanced cancer patients with cancer-related anorexia/cachexia and oxidative stress.</jats:p>
<jats:p>Patients and Methods: An open early-phase II study was designed according to the Simon two-stage design. The integrated treatment consisted of diet with high polyphenols content (400 mg), antioxidant treatment (300 mg/d α-lipoic acid + 2.7 g/d carbocysteine lysine salt + 400 mg/d vitamin E + 30,000 IU/d vitamin A + 500 mg/d vitamin C), and pharmaconutritional support enriched with 2 cans per day (n-3)-PUFA (eicosapentaenoic acid and docosahexaenoic acid), 500 mg/d medroxyprogesterone acetate, and 200 mg/d selective cyclooxygenase-2 inhibitor celecoxib. The treatment duration was 4 months. The following variables were evaluated: (a) clinical (Eastern Cooperative Oncology Group performance status); (b) nutritional [lean body mass (LBM), appetite, and resting energy expenditure]; (c) laboratory [proinflammatory cytokines and leptin, reactive oxygen species (ROS) and antioxidant enzymes]; (d) quality of life (European Organization for Research and Treatment of Cancer QLQ-C30, Euro QL-5D, and MFSI-SF).</jats:p>
<jats:p>Results: From July 2002 to January 2005, 44 patients were enrolled. Of these, 39 completed the treatment and were assessable. Body weight increased significantly from baseline as did LBM and appetite. There was an important decrease of proinflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-α, and a negative relationship worthy of note was only found between LBM and IL-6 changes. As for quality of life evaluation, there was a marked improvement in the European Organization for Research and Treatment of Cancer QLQ-C30, Euro QL-5DVAS, and multidimensional fatigue symptom inventory-short form scores. At the end of the study, 22 of the 39 patients were “responders” or “high responders.” The minimum required was 21; therefore, the treatment was effective and more importantly was shown to be safe.</jats:p>
<jats:p>Conclusion: The efficacy and safety of the treatment have been shown by the study; therefore, a randomized phase III study is warranted. (Cancer Epidemiol Biomarkers Prev 2006;15(5):1030–4)</jats:p> |
| container_issue |
5 |
| container_start_page |
1030 |
| container_title |
Cancer Epidemiology, Biomarkers & Prevention |
| container_volume |
15 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792345357525450772 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:22:12.939Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=A+Phase+II+Study+with+Antioxidants%2C+Both+in+the+Diet+and+Supplemented%2C+Pharmaconutritional+Support%2C+Progestagen%2C+and+Anti-Cyclooxygenase-2+Showing+Efficacy+and+Safety+in+Patients+with+Cancer-Related+Anorexia%2FCachexia+and+Oxidative+Stress&rft.date=2006-05-01&genre=article&issn=1538-7755&volume=15&issue=5&spage=1030&epage=1034&pages=1030-1034&jtitle=Cancer+Epidemiology%2C+Biomarkers+%26+Prevention&atitle=A+Phase+II+Study+with+Antioxidants%2C+Both+in+the+Diet+and+Supplemented%2C+Pharmaconutritional+Support%2C+Progestagen%2C+and+Anti-Cyclooxygenase-2+Showing+Efficacy+and+Safety+in+Patients+with+Cancer-Related+Anorexia%2FCachexia+and+Oxidative+Stress&aulast=Deiana&aufirst=Laura&rft_id=info%3Adoi%2F10.1158%2F1055-9965.epi-05-0538&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792345357525450772 |
| author | Mantovani, Giovanni, Macciò, Antonio, Madeddu, Clelia, Gramignano, Giulia, Lusso, Maria Rita, Serpe, Roberto, Massa, Elena, Astara, Giorgio, Deiana, Laura |
| author_facet | Mantovani, Giovanni, Macciò, Antonio, Madeddu, Clelia, Gramignano, Giulia, Lusso, Maria Rita, Serpe, Roberto, Massa, Elena, Astara, Giorgio, Deiana, Laura, Mantovani, Giovanni, Macciò, Antonio, Madeddu, Clelia, Gramignano, Giulia, Lusso, Maria Rita, Serpe, Roberto, Massa, Elena, Astara, Giorgio, Deiana, Laura |
| author_sort | mantovani, giovanni |
| container_issue | 5 |
| container_start_page | 1030 |
| container_title | Cancer Epidemiology, Biomarkers & Prevention |
| container_volume | 15 |
| description | <jats:title>Abstract</jats:title> <jats:p>Purpose: To test the efficacy and safety of an integrated treatment based on a pharmaconutritional support, antioxidants, and drugs, all given orally, in a population of advanced cancer patients with cancer-related anorexia/cachexia and oxidative stress.</jats:p> <jats:p>Patients and Methods: An open early-phase II study was designed according to the Simon two-stage design. The integrated treatment consisted of diet with high polyphenols content (400 mg), antioxidant treatment (300 mg/d α-lipoic acid + 2.7 g/d carbocysteine lysine salt + 400 mg/d vitamin E + 30,000 IU/d vitamin A + 500 mg/d vitamin C), and pharmaconutritional support enriched with 2 cans per day (n-3)-PUFA (eicosapentaenoic acid and docosahexaenoic acid), 500 mg/d medroxyprogesterone acetate, and 200 mg/d selective cyclooxygenase-2 inhibitor celecoxib. The treatment duration was 4 months. The following variables were evaluated: (a) clinical (Eastern Cooperative Oncology Group performance status); (b) nutritional [lean body mass (LBM), appetite, and resting energy expenditure]; (c) laboratory [proinflammatory cytokines and leptin, reactive oxygen species (ROS) and antioxidant enzymes]; (d) quality of life (European Organization for Research and Treatment of Cancer QLQ-C30, Euro QL-5D, and MFSI-SF).</jats:p> <jats:p>Results: From July 2002 to January 2005, 44 patients were enrolled. Of these, 39 completed the treatment and were assessable. Body weight increased significantly from baseline as did LBM and appetite. There was an important decrease of proinflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-α, and a negative relationship worthy of note was only found between LBM and IL-6 changes. As for quality of life evaluation, there was a marked improvement in the European Organization for Research and Treatment of Cancer QLQ-C30, Euro QL-5DVAS, and multidimensional fatigue symptom inventory-short form scores. At the end of the study, 22 of the 39 patients were “responders” or “high responders.” The minimum required was 21; therefore, the treatment was effective and more importantly was shown to be safe.</jats:p> <jats:p>Conclusion: The efficacy and safety of the treatment have been shown by the study; therefore, a randomized phase III study is warranted. (Cancer Epidemiol Biomarkers Prev 2006;15(5):1030–4)</jats:p> |
| doi_str_mv | 10.1158/1055-9965.epi-05-0538 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDU1LTk5NjUuZXBpLTA1LTA1Mzg |
| imprint | American Association for Cancer Research (AACR), 2006 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2006 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 1055-9965, 1538-7755 |
| issn_str_mv | 1055-9965, 1538-7755 |
| language | English |
| last_indexed | 2024-03-01T17:22:12.939Z |
| match_str | mantovani2006aphaseiistudywithantioxidantsbothinthedietandsupplementedpharmaconutritionalsupportprogestagenandanticyclooxygenase2showingefficacyandsafetyinpatientswithcancerrelatedanorexiacachexiaandoxidativestress |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 1030-1034 |
| publishDate | 2006 |
| publishDateSort | 2006 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Cancer Epidemiology, Biomarkers & Prevention |
| source_id | 49 |
| spelling | Mantovani, Giovanni Macciò, Antonio Madeddu, Clelia Gramignano, Giulia Lusso, Maria Rita Serpe, Roberto Massa, Elena Astara, Giorgio Deiana, Laura 1055-9965 1538-7755 American Association for Cancer Research (AACR) Oncology Epidemiology http://dx.doi.org/10.1158/1055-9965.epi-05-0538 <jats:title>Abstract</jats:title> <jats:p>Purpose: To test the efficacy and safety of an integrated treatment based on a pharmaconutritional support, antioxidants, and drugs, all given orally, in a population of advanced cancer patients with cancer-related anorexia/cachexia and oxidative stress.</jats:p> <jats:p>Patients and Methods: An open early-phase II study was designed according to the Simon two-stage design. The integrated treatment consisted of diet with high polyphenols content (400 mg), antioxidant treatment (300 mg/d α-lipoic acid + 2.7 g/d carbocysteine lysine salt + 400 mg/d vitamin E + 30,000 IU/d vitamin A + 500 mg/d vitamin C), and pharmaconutritional support enriched with 2 cans per day (n-3)-PUFA (eicosapentaenoic acid and docosahexaenoic acid), 500 mg/d medroxyprogesterone acetate, and 200 mg/d selective cyclooxygenase-2 inhibitor celecoxib. The treatment duration was 4 months. The following variables were evaluated: (a) clinical (Eastern Cooperative Oncology Group performance status); (b) nutritional [lean body mass (LBM), appetite, and resting energy expenditure]; (c) laboratory [proinflammatory cytokines and leptin, reactive oxygen species (ROS) and antioxidant enzymes]; (d) quality of life (European Organization for Research and Treatment of Cancer QLQ-C30, Euro QL-5D, and MFSI-SF).</jats:p> <jats:p>Results: From July 2002 to January 2005, 44 patients were enrolled. Of these, 39 completed the treatment and were assessable. Body weight increased significantly from baseline as did LBM and appetite. There was an important decrease of proinflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-α, and a negative relationship worthy of note was only found between LBM and IL-6 changes. As for quality of life evaluation, there was a marked improvement in the European Organization for Research and Treatment of Cancer QLQ-C30, Euro QL-5DVAS, and multidimensional fatigue symptom inventory-short form scores. At the end of the study, 22 of the 39 patients were “responders” or “high responders.” The minimum required was 21; therefore, the treatment was effective and more importantly was shown to be safe.</jats:p> <jats:p>Conclusion: The efficacy and safety of the treatment have been shown by the study; therefore, a randomized phase III study is warranted. (Cancer Epidemiol Biomarkers Prev 2006;15(5):1030–4)</jats:p> A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmaconutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress Cancer Epidemiology, Biomarkers & Prevention |
| spellingShingle | Mantovani, Giovanni, Macciò, Antonio, Madeddu, Clelia, Gramignano, Giulia, Lusso, Maria Rita, Serpe, Roberto, Massa, Elena, Astara, Giorgio, Deiana, Laura, Cancer Epidemiology, Biomarkers & Prevention, A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmaconutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress, Oncology, Epidemiology |
| title | A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmaconutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress |
| title_full | A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmaconutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress |
| title_fullStr | A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmaconutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress |
| title_full_unstemmed | A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmaconutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress |
| title_short | A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmaconutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress |
| title_sort | a phase ii study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress |
| title_unstemmed | A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmaconutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress |
| topic | Oncology, Epidemiology |
| url | http://dx.doi.org/10.1158/1055-9965.epi-05-0538 |